Safety of disclosing amyloid status in cognitively normal older adults

Jeffrey M. Burns, David K Johnson, Edward P. Liebmann, Rebecca J. Bothwell, Jill K. Morris, Eric D. Vidoni

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Introduction Disclosing amyloid status to cognitively normal individuals remains controversial given our lack of understanding the test's clinical significance and unknown psychological risk. Methods We assessed the effect of amyloid status disclosure on anxiety and depression before disclosure, at disclosure, and 6 weeks and 6 months postdisclosure and test-related distress after disclosure. Results Clinicians disclosed amyloid status to 97 cognitively normal older adults (27 had elevated cerebral amyloid). There was no difference in depressive symptoms across groups over time. There was a significant group by time interaction in anxiety, although post hoc analyses revealed no group differences at any time point, suggesting a minimal nonsustained increase in anxiety symptoms immediately postdisclosure in the elevated group. Slight but measureable increases in test-related distress were present after disclosure and were related to greater baseline levels of anxiety and depression. Discussion Disclosing amyloid imaging results to cognitively normal adults in the clinical research setting with pre- and postdisclosure counseling has a low risk of psychological harm.

Original languageEnglish (US)
Pages (from-to)1024-1030
Number of pages7
JournalAlzheimer's and Dementia
Volume13
Issue number9
DOIs
StatePublished - Sep 1 2017
Externally publishedYes

Fingerprint

Disclosure
Amyloid
Safety
Anxiety
Depression
Psychology
Counseling
Research

Keywords

  • Amyloid PET imaging
  • Anxiety
  • Biomedical ethics
  • Depression
  • Diagnostic imaging
  • Preclinical Alzheimer's disease
  • Safety
  • Truth disclosure

ASJC Scopus subject areas

  • Epidemiology
  • Health Policy
  • Developmental Neuroscience
  • Clinical Neurology
  • Geriatrics and Gerontology
  • Cellular and Molecular Neuroscience
  • Psychiatry and Mental health

Cite this

Burns, J. M., Johnson, D. K., Liebmann, E. P., Bothwell, R. J., Morris, J. K., & Vidoni, E. D. (2017). Safety of disclosing amyloid status in cognitively normal older adults. Alzheimer's and Dementia, 13(9), 1024-1030. https://doi.org/10.1016/j.jalz.2017.01.022

Safety of disclosing amyloid status in cognitively normal older adults. / Burns, Jeffrey M.; Johnson, David K; Liebmann, Edward P.; Bothwell, Rebecca J.; Morris, Jill K.; Vidoni, Eric D.

In: Alzheimer's and Dementia, Vol. 13, No. 9, 01.09.2017, p. 1024-1030.

Research output: Contribution to journalArticle

Burns, JM, Johnson, DK, Liebmann, EP, Bothwell, RJ, Morris, JK & Vidoni, ED 2017, 'Safety of disclosing amyloid status in cognitively normal older adults', Alzheimer's and Dementia, vol. 13, no. 9, pp. 1024-1030. https://doi.org/10.1016/j.jalz.2017.01.022
Burns, Jeffrey M. ; Johnson, David K ; Liebmann, Edward P. ; Bothwell, Rebecca J. ; Morris, Jill K. ; Vidoni, Eric D. / Safety of disclosing amyloid status in cognitively normal older adults. In: Alzheimer's and Dementia. 2017 ; Vol. 13, No. 9. pp. 1024-1030.
@article{c141c3a6ecd2488a95c8060fcade6210,
title = "Safety of disclosing amyloid status in cognitively normal older adults",
abstract = "Introduction Disclosing amyloid status to cognitively normal individuals remains controversial given our lack of understanding the test's clinical significance and unknown psychological risk. Methods We assessed the effect of amyloid status disclosure on anxiety and depression before disclosure, at disclosure, and 6 weeks and 6 months postdisclosure and test-related distress after disclosure. Results Clinicians disclosed amyloid status to 97 cognitively normal older adults (27 had elevated cerebral amyloid). There was no difference in depressive symptoms across groups over time. There was a significant group by time interaction in anxiety, although post hoc analyses revealed no group differences at any time point, suggesting a minimal nonsustained increase in anxiety symptoms immediately postdisclosure in the elevated group. Slight but measureable increases in test-related distress were present after disclosure and were related to greater baseline levels of anxiety and depression. Discussion Disclosing amyloid imaging results to cognitively normal adults in the clinical research setting with pre- and postdisclosure counseling has a low risk of psychological harm.",
keywords = "Amyloid PET imaging, Anxiety, Biomedical ethics, Depression, Diagnostic imaging, Preclinical Alzheimer's disease, Safety, Truth disclosure",
author = "Burns, {Jeffrey M.} and Johnson, {David K} and Liebmann, {Edward P.} and Bothwell, {Rebecca J.} and Morris, {Jill K.} and Vidoni, {Eric D.}",
year = "2017",
month = "9",
day = "1",
doi = "10.1016/j.jalz.2017.01.022",
language = "English (US)",
volume = "13",
pages = "1024--1030",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
publisher = "Elsevier Inc.",
number = "9",

}

TY - JOUR

T1 - Safety of disclosing amyloid status in cognitively normal older adults

AU - Burns, Jeffrey M.

AU - Johnson, David K

AU - Liebmann, Edward P.

AU - Bothwell, Rebecca J.

AU - Morris, Jill K.

AU - Vidoni, Eric D.

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Introduction Disclosing amyloid status to cognitively normal individuals remains controversial given our lack of understanding the test's clinical significance and unknown psychological risk. Methods We assessed the effect of amyloid status disclosure on anxiety and depression before disclosure, at disclosure, and 6 weeks and 6 months postdisclosure and test-related distress after disclosure. Results Clinicians disclosed amyloid status to 97 cognitively normal older adults (27 had elevated cerebral amyloid). There was no difference in depressive symptoms across groups over time. There was a significant group by time interaction in anxiety, although post hoc analyses revealed no group differences at any time point, suggesting a minimal nonsustained increase in anxiety symptoms immediately postdisclosure in the elevated group. Slight but measureable increases in test-related distress were present after disclosure and were related to greater baseline levels of anxiety and depression. Discussion Disclosing amyloid imaging results to cognitively normal adults in the clinical research setting with pre- and postdisclosure counseling has a low risk of psychological harm.

AB - Introduction Disclosing amyloid status to cognitively normal individuals remains controversial given our lack of understanding the test's clinical significance and unknown psychological risk. Methods We assessed the effect of amyloid status disclosure on anxiety and depression before disclosure, at disclosure, and 6 weeks and 6 months postdisclosure and test-related distress after disclosure. Results Clinicians disclosed amyloid status to 97 cognitively normal older adults (27 had elevated cerebral amyloid). There was no difference in depressive symptoms across groups over time. There was a significant group by time interaction in anxiety, although post hoc analyses revealed no group differences at any time point, suggesting a minimal nonsustained increase in anxiety symptoms immediately postdisclosure in the elevated group. Slight but measureable increases in test-related distress were present after disclosure and were related to greater baseline levels of anxiety and depression. Discussion Disclosing amyloid imaging results to cognitively normal adults in the clinical research setting with pre- and postdisclosure counseling has a low risk of psychological harm.

KW - Amyloid PET imaging

KW - Anxiety

KW - Biomedical ethics

KW - Depression

KW - Diagnostic imaging

KW - Preclinical Alzheimer's disease

KW - Safety

KW - Truth disclosure

UR - http://www.scopus.com/inward/record.url?scp=85019653354&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019653354&partnerID=8YFLogxK

U2 - 10.1016/j.jalz.2017.01.022

DO - 10.1016/j.jalz.2017.01.022

M3 - Article

VL - 13

SP - 1024

EP - 1030

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

SN - 1552-5260

IS - 9

ER -